- Extensive animal/laboratory literature reports activity across multiple injury models.
- Human exposure evidence remains sparse and does not establish efficacy.
- FDA reviewed BPC-157-related bulk substances for ulcerative colitis in July 2026.
RESEARCH REBEL • EVIDENCE DOSSIER
BPC-157
PRECLINICAL DOMINANT • LIMITED HUMAN DATAA synthetic 15-amino-acid peptide with a large preclinical literature but a major translational gap. A 2026 review reports no approved formulation, no validated dosing regimen and no completed Phase II trial.
- Human PK across commonly discussed routes.
- Validated human dose-response.
- Long-term safety and immunogenicity for research/compounded preparations.
PUBLISHED PROTOCOL EVIDENCE
Study parameter ≠ universal protocol.
Published human evidence does not establish a validated general dosing regimen. Animal-study amounts remain preclinical study parameters and are not converted into human dosing.
Numerical study entries carry:PopulationRouteFormulationAmountFrequencyDurationEndpointSource
COMMUNITY EVIDENCE
Document it. Don't upgrade it.
Community reports commonly discuss GI symptoms, injury recovery and inflammation. These are hypothesis-generating and highly confounded.
Reported amount/rangeRouteFrequencyDurationGoalReported positivesReported negativesConcurrent compoundsSource + N
COMMUNITY-REPORTED • NOT CLINICALLY VALIDATED